Biotech Series B Investors & VC Firms
900 firms in this list, with a median first check of $550K. 188 of them lead rounds. Generated from verified public data and updated continuously.
DOMiNO Ventures
AmsterdamSeed–Series B$220K – $1.1M
30 people
GroveStreet
NewtonSeries A–Late Stage
39 people
Karista
ParisPre-Seed–Late Stage$324K – $5.4M
14 people
Safar Partners
CambridgePre-Seed–Late Stage
20 people
PMV
BrusselsPre-Seed–Late Stage
1 person
UTEC
TokyoPre-Seed–Growth$3.1M – $78M
1 person
Hoxton Ventures
LondonPre-Seed–Series B$500K – $5M
16 people
aMoon
Ra'ananaSeed–Late Stage
25 people
Impact Fund Denmark
CopenhagenSeed–Late Stage$2.2M – $70.2M
36 people
McWin Capital Partners
LondonSeries B–Late Stage
31 people
Rho Ventures
New YorkPre-Seed–Late Stage$2M – $15M
10 people
Claret Capital Partners
LondonSeries A–Late Stage
29 people
Novartis Venture Fund
BaselPre-Seed–Late Stage$5M – $25M
25 people
CEI Ventures
BrunswickSeed–Late Stage$1M – $4M
18 people
EcoR1 Capital
San FranciscoSeed–Late Stage
17 people
EMV Capital
LondonPre-Seed–Series B
20 people
Movac
AucklandSeed–Late Stage$600K – $3M
26 people
BioMedPartners
BaselSeed–Late Stage$648K – $6.5M
28 people
LDC
LondonSeries B–Growth$12.7M – $127M
12 people
Dreamers VC
El SegundoSeed–Series B$500K – $5M
8 people
Material Impact
BostonSeed–Series B$100K – $10M
22 people
Next Level Ventures
Des MoinesSeed–Late Stage$500K – $5M
16 people
Parkwalk Advisors
LondonSeed–Growth
31 people
Signal Peak Ventures
Salt Lake CityPre-Seed–Series B$250K – $5M
17 people
Related lists
Series B Investors & VC Firms (4094)Biotech Investors & VC Firms (2107)Biotech Seed Investors & VC Firms (1754)Series B Investors & VC Firms in United States (1625)Biotech Series A Investors & VC Firms (1596)SaaS Series B Investors & VC Firms (1317)Series B Investors & VC Firms in Global (1265)Enterprise Software Series B Investors & VC Firms (1242)Healthtech Series B Investors & VC Firms (1216)Fintech Series B Investors & VC Firms (1141)
Data sourced from public filings and firms' own websites — see our methodology.











































































